Compositions and methods for diagnosis and treatment of cancer
AssigneeBioNTech SE
InventorsUgur Sahin, Joycelyn Wüstehube-Lausch, Markus Fiedler, Matin Daneschdar, Hans-Ulrich Schmoldt
Life of this patent
Estimating the term…
Abstract
The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.
Claims16
A Seprase binding peptide which comprises the amino acid sequence Gly Arg Gly Pro (SEQ ID NO:
- 5), wherein
- (a) the Seprase binding peptide forms and/or is part of a cystine knot structure containing at least three disulphide bridges formed from pairs of cysteine molecules, and
- (b) the amino acid sequence Gly Arg Gly Pro (SEQ ID NO:
- 5) is part of the cystine knot structure wherein the amino acid sequence is located between the first cysteine and the second cysteine of the cystine knot structure.
A Seprase binding peptide comprising the amino acid sequence:
- (SEQ ID NO:
- 23)
- Gly Ala Cys Pro Tyr Ser Asn Trp Thr Pro Gly Arg
- Gly Pro Asp Cys Arg Arg Asp Ser Asp Cys Pro Gly
- Arg Cys Ile Cys Arg Gly Asn Gly Tyr Cys Gly.
A Seprase binding peptide comprising the amino acid sequence Gly Arg Gly Pro (SEQ ID NO:
- 5) and at least one fusion partner.
A Seprase binding agent comprising the amino acid sequence Gly Arg Gly Pro (SEQ ID NO:
- 5) covalently and/or non-covalently associated with at least one further moiety.
Dependencies are inferred from the claim text.